Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline

Fertility and Sterility

Volumn 106, Issue 7, 2016, Pages 1634-1647

  Pfeifer, Samantha ^a   Butts, Samantha ^a   Dumesic, Daniel ^a   Fossum, Gregory ^a   Gracia, Clarisa ^a   La Barbera, Andrew ^a   Mersereau, Jennifer ^a   Odem, Randall ^a   Paulson, Richard ^a   Penzias, Alan ^a   Pisarska, Margareta ^a   Rebar, Robert ^a   Reindollar, Richard ^a   Rosen, Mitchell ^a   Sandlow, Jay ^a   Vernon, Michael ^a   Widra, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CALCIUM; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; INHIBIN A; INHIBIN B; METFORMIN; MUELLERIAN INHIBITING FACTOR;

ARTICLE; BODY MASS; CLINICAL FEATURE; CLINICAL PROTOCOL; CRYOPRESERVATION; DISEASE SEVERITY; FEMALE; FEMALE INFERTILITY; HIGH RISK POPULATION; HUMAN; OOCYTE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PARACENTESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG EFFECTS; INFERTILITY; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STANDARDS; TREATMENT OUTCOME;

FEMALE; HUMANS; INFERTILITY; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION; OVULATION INDUCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84996523469     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2016.08.048     Document Type: Article

References (113)

1. 1 Steward, R.G., Lan, L., Shah, A.A., Yeh, J.S., Price, T.M., Goldfarb, J.M., et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 101 (2014), 967–973 Level II-2.
2. 2 Luke, B., Brown, M.B., Morbeck, D.E., Hudson, S.B., Coddington, C.C. 3rd, Stern, J.E., Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 94 (2010), 1399–1404 Level II-2.
3. 3 Jayaprakasan, K., Chan, Y., Islam, R., Haoula, Z., Hopkisson, J., Coomarasamy, A., et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 98 (2012), 657–663 Level II-2.
4. 4 Kahnberg, A., Enskog, A., Brännström, M., Lundin, K., Bergh, C., Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Acta Obstet Gynecol Scand 88 (2009), 1373–1381 Level II-2.
5. 5 Papanikolaou, E.G., Pozzobon, C., Kolibianakis, E.M., Camus, M., Tournaye, H., Fatemi, H.M., et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85 (2006), 112–120 Level II-2.
6. 6 Goldsman, M.P., Pedram, A., Dominguez, C.E., Ciuffardi, I., Levin, E., Asch, R.H., Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 63 (1995), 268–272 Level II-2.
7. 7 Bergh, P.A., Navot, D., Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 9 (1992), 429–438 Level III.
8. 8 Geva, E., Jaffe, R.B., Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74 (2000), 429–438 Level III.
9. 9 Levin, E.R., Rosen, G.F., Cassidenti, D.L., Yee, B., Meldrum, D., Wisot, A., et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 102 (1998), 1978–1985 Level II-2.
10. 10 Neulen, J., Yan, Z., Raczek, S., Weindel, K., Keek, C., Weich, H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80 (1995), 1967–1971 Level II-3.
11. 11 McClure, N., Healy, D.L., Rogers, P.A., Sullivan, J., Beaton, L., Haning, R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 (1994), 235–236 Level II-2.
12. 12 Pellicer, A., Albert, C., Mercader, A., Bonilla-Musoles, F., Remohi, J., Simon, C., The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1b, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71 (1999), 482–489 Level II-2.
13. 13 Whelan, J.G. 3rd, Vlahos, N.F., The ovarian hyperstimulation syndrome. Fertil Steril 73 (2000), 883–896 Level III.
14. 14 Revel, A., Barak, V., Lavy, Y., Anteby, E., Abramov, Y., Schenker, J.J., et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 66 (1996), 66–71 Level II-1.
15. 15 Delbaere, A., Bergmann, P.J.M., Gervy-Decoster, C., Deschodt-Lanckman, M., de Maertelaer, V., Staroukine, M., et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril 67 (1997), 1038–1045 Level II-2.
16. 16 Morris, R.S., Wong, I.L., Kirkman, E., Gentschein, E., Paulson, R.J., Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 10 (1995), 1355–1358.
17. 17 Ashrafi, M., Bahmanabadi, A., Akhond, M.R., Arabipoor, A., Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model. Arch Gynecol Obstet 292 (2015), 1145–1152 Level II-2.
18. 18 Johnson, M.D., Williams, S.L., Seager, C.K., Liu, J.H., Barker, N.M., Hurd, W.W., Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome. Gynecol Endocrinol 30 (2014), 294–297 Level II-2.
19. 19 Sousa, M., Cunha, M., Teixeira da Silva, J., Oliveira, C., Silva, J., Viana, P., et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol, 13, 2015, 66 Level II-2.
20. 20 Mathur, R.S., Akande, A.V., Keay, S.D., Hunt, L.P., Jenkins, J.M., Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73 (2000), 901–907 Level II-2.
21. 21 Aramwit, P., Pruksananonda, K., Kasettratat, N., Jammeechai, K., Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 65 (2008), 1148–1153 Level II-2.
22. 22 Danninger, B., Brunner, M., Obruca, A., Feichtinger, W., Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation. Hum Reprod 11 (1996), 1597–1599 Level II-2.
23. 23 Delvigne, A., Demoulin, A., Smitz, J., Donnez, J., Koninckx, P., Dhont, M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 8 (1993), 1353–1360 Level II-2.
24. 24 Lee, T.H., Liu, C.H., Huang, C.C., Wu, Y.L., Shih, Y.T., Ho, H.N., et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 23 (2008), 160–167 Level II-2.
25. 25 Swanton, A., Storey, L., McVeigh, E., Child, T., IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol 149 (2010), 68–71 Level II-2.
26. 26 Nakhuda, G.S., Chu, M.C., Wang, J.G., Sauer, M.V., Lobo, R.A., Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 85 (2006), 1541–1543 Level II-2.
27. 27 Tal, R., Seifer, D.B., Khanimov, M., Malter, H.E., Grazi, R.V., Leader, B., Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 211 (2014), 59.e1–59.e8 Level II-2.
28. 28 Ocal, P., Sahmay, S., Cetin, M., Irez, T., Guralp, O., Cepni, I., Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 28 (2011), 1197–1203 Level II-2.
29. 29 Moos, J., Rezabek, K., Filova, V., Moosova, M., Pavelkova, J., Peknicova, J., Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients. Reprod Biol Endocrinol, 7, 2009, 86 Level II-2.
30. 30 Jayaprakasan, K., Herbert, M., Moody, E., Stewart, J.A., Murdoch, A.P., Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research. Hum Fertil (Camb) 10 (2007), 183–187 Level II-2.
31. 31 D'Angelo, A., Davies, R., Salah, E., Nix, B.A., Amso, N.N., Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 81 (2004), 332–336 Level II-2.
32. 32 Reljic, M., Vlaisavljevic, V., Gavric, V., Kovacic, B., Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome. J Reprod Med 44 (1999), 713–718 Level II-2.
33. 33 Hendriks, D.J., Klinkert, E.R., Bancsi, L.F., Looman, C.W., Habbema, J.D., te Velde, E.R., et al. Use of stimulated serum estradiol measurements for the prediction of hyperresponse to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet 21 (2004), 65–72 Level II-2.
34. 34 Toftager, M., Bogstad, J., Bryndorf, T., Løssl, K., Roskær, J., Holland, T., et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod, 2016 [Epub ahead of print]. Level I.
35. 35 Ludwig, M., Felberbaum, R.E., Devroey, P., Albano, C., Riethmuller-Winzen, H., Schuler, A., et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 264 (2000), 29–32 Level I.
36. 36 Qiao, J., Lu, G., Zhang, H.W., Chen, H., Ma, C., Olofsson, J.I., et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecol Endocrinol 28 (2012), 800–804 Level I.
37. 37 Borm, G., Mannaerts, B., Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15 (2000), 1490–1498 Level I.
38. 38 Borges, E. Jr., Braga, D.P., Setti, A.S., Vingris, L.S., Figueira, R.C., Iaconelli, A. Jr., Strategies for the management of OHSS: Results from freezing-all cycles. JBRA Assist Reprod 20 (2016), 8–12 Level II-2.
39. 39 Firouzabadi, R.D., Ahmadi, S., Oskouian, H., Davar, R., Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Arch Gynecol Obstet 281 (2010), 81–85 Level I.
40. 40 Hosseini, M.A., Aleyasin, A., Saeedi, H., Mahdavi, A., Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. J Obstet Gynaecol Res 36 (2010), 605–610 Level I.
41. 41 Lainas, T.G., Sfontouris, I.A., Zorzovilis, I.Z., Petsas, G.K., Lainas, G.T., Alexopoulou, E., et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod 25 (2010), 683–689 Level I.
42. 42 Ludwig, M., Katalinic, A., Diedrich, K., Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 265 (2001), 175–182 Level III.
43. 43 Mancini, F., Tur, R., Martinez, F., Coroleu, B., Rodriguez, I., Barri, P.N., Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 27 (2011), 150–155 Level III.
44. 44 Xiao, J., Chen, S., Zhang, C., Chang, S., Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis. Gynecol Endocrinol 29 (2013), 187–191 Level III.
45. 45 Xiao, J.S., Su, C.M., Zeng, X.T., Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One, 9, 2014, e106854 Level III.
46. 46 Al-Inany, H.G., Youssef, M.A., Aboulghar, M., Broekmans, F., Sterrenburg, M., Smit, J., et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev, 2011, CD001750 Level III.
47. 47 Weigert, M., Krischker, U., Pohl, M., Poschalko, G., Kindermann, C., Feichtinger, W., Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil Steril 78 (2002), 34–39 Level I.
48. 48 Karimzadeh, M.A., Ahmadi, S., Oskouian, H., Rahmani, E., Comparison of mild stimulation and conventional stimulation in ART outcome. Arch Gynecol Obstet 281 (2010), 741–746 Level I.
49. 49 Figueiredo, J.B., Nastri, C.O., Vieira, A.D., Martins, W.P., Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis. Arch Gynecol Obstet 287 (2013), 779–790 Level III.
50. 50 Gibreel, A., Maheshwari, A., Bhattacharya, S., Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev, 11, 2012, CD008528 Level III.
51. 51 Varnagy, A., Bodis, J., Manfai, Z., Wilhelm, F., Busznyák, C., Koppán, M., Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 93 (2010), 2281–2284 Level I.
52. 52 Revelli, A., Dolfin, E., Gennarelli, G., Lantieri, T., Massobrio, M., Holte, J.G., et al. Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study. Fertil Steril 90 (2008), 1685–1691 Level I.
53. 53 Tang, T., Glanville, J., Orsi, N., Barth, J.H., Balen, A.H., The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21 (2006), 1416–1425 Level I.
54. 54 Palomba, S., Falbo, A., Carrillo, L., Villani, M.T., Orio, F., Russo, T., et al., METformin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 96 (2011), 1384–1390.e4 Level I.
55. 55 Qublan, H.S., Al-Khaderei, S., Abu-Salem, A.N., Al-Zpoon, A., Al-Khateeb, M., Al-Ibrahim, N., et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. J Obstet Gynaecol 29 (2009), 651–655 Level I.
56. 56 Palomba, S., Falbo, A., La Sala, G.B., Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 120 (2013), 267–276 Level III.
57. 57 Huang, X., Wang, P., Tal, R., Lv, F., Li, Y., Zhang, X., A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. Int J Gynaecol Obstet 131 (2015), 111–116 Level III.
58. 58 Kumbak, B., Kahraman, S., Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. Acta Obstet Gynecol Scand 88 (2009), 563–568 Level II-2.
59. 59 Swanton, A., Lighten, A., Granne, I., McVeigh, E., Lavery, S., Trew, G., et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Hum Reprod 26 (2011), 2178–2184 Level I.
60. 60 Al-Shawaf, T., Zosmer, A., Hussain, S., Tozer, A., Panay, N., Wilson, C., et al. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients. Hum Reprod 16 (2001), 24–30 Level II-2.
61. 61 Dhont, M., Van der Straeten, F., De Sutter, P., Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril 70 (1998), 847–850 Level II-2.
62. 62 Gera, P.S., Tatpati, L.L., Allemand, M.C., Wentworth, M.A., Coddington, C.C., Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome. Fertil Steril 94 (2010), 173–178 Level II-2.
63. 63 Chen, C.D., Chao, K.H., Yang, J.H., Chen, S.U., Ho, H.N., Yang, Y.S., Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 80 (2003), 86–90 Level II-2.
64. 64 Egbase, P.E., Sharhan, M.A., Grudzinskas, J.G., Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 14 (1999), 1421–1425 Level I.
65. 65 D'Angelo, A., Brown, J., Amso, N.N., Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev, 2001, CD002811 Level III.
66. 66 Lee, C., Tummon, I., Martin, J., Nisker, J., Power, S., Tekpetey, F., Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?. Hum Reprod 13 (1998), 1157–1158 Level II-2.
67. 67 Nardo, L.G., Cheema, P., Gelbaya, T.A., Horne, G., Fitzgerald, C.T., Pease, E.H., et al. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization. Hum Fertil (Camb) 9 (2006), 175–180 Level II-2.
68. 68 Shaltout, A.M., Eid, M., Shohayeb, A., Does triggering ovulation by 5000 IU of uhCG affect ICSI outcome?. Middle East Fertil Soc J 11 (2006), 99–103 Level I.
69. 69 Lin, H., Wang, W., Li, Y., Chen, X., Yang, D., Zhang, Q., Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study. Eur J Obstet Gynecol Reprod Biol 159 (2011), 143–147 Level I.
70. 70 Engmann, L., DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., Benadiva, C., The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89 (2008), 84–91 Level I.
71. 71 Galindo, A., Bodri, D., Guillen, J.J., Colodron, M., Vernaeve, V., Coll, O., Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 25 (2009), 60–66 Level I.
72. 72 Melo, M., Busso, C.E., Bellver, J., Alama, P., Garrido, N., Meseguer, M., et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 19 (2009), 486–492 Level I.
73. 73 Sismanoglu, A., Tekin, H.I., Erden, H.F., Ciray, N.H., Ulug, U., Bahceci, M., Ovulation triggering with GnRH agonist vs hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet 26 (2009), 251–256 Level I.
74. 74 Bodri, D., Guillen, J.J., Polo, A., Trullenque, M., Esteve, C., Coll, O., Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reprod Biomed Online 17 (2008), 237–243 Level II-2.
75. 75 Imbar, T., Kol, S., Lossos, F., Bdolah, Y., Hurwitz, A., Haimov-Kochman, R., Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 27 (2012), 753–759 Level II-2.
76. 76 Oktay, K., Turkcuoglu, I., Rodriguez-Wallberg, K.A., GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 20 (2010), 783–788 Level II-2.
77. 77 Orvieto, R., Rabinson, J., Meltzer, S., Zohav, E., Anteby, E., Homburg, R., Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 13 (2006), 198–201 Level II-2.
78. 78 Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Mochtar, M.H., Griesinger, G., Nagi Mohesen, M., et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev, 2014, CD008046 Level III.
79. 79 Humaidan, P., Polyzos, N.P., Alsbjerg, B., Erb, K., Mikkelsen, A.L., Elbaek, H.O., et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 28 (2013), 2511–2521 Level I.
80. 80 Castillo, J.C., Dolz, M., Bienvenido, E., Abad, L., Casan, E.M., Bonilla-Musoles, F., Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 20 (2010), 175–181 Level II-2.
81. 81 Meyer, L., Murphy, L.A., Gumer, A., Reichman, D.E., Rosenwaks, Z., Cholst, I.N., Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril 104 (2015), 637–642 Level II-2.
82. 82 Tehraninejad, E.S., Hafezi, M., Arabipoor, A., Aziminekoo, E., Chehrazi, M., Bahmanabadi, A., Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 29 (2012), 259–264 Level I.
83. 83 Torabizadeh, A., Vahidroodsari, F., Ghorbanpour, Z., Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study. Iran J Reprod Med 11 (2013), 837–842 Level I.
84. 84 Alvarez, C., Marti-Bonmati, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92 (2007), 2931–2937 Level I.
85. 85 Amir, H., Yaniv, D., Hasson, J., Amit, A., Gordon, D., Azem, F., Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. J Reprod Med 60 (2015), 48–54 Level I.
86. 86 Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17 (2008), 751–755 Level I.
87. 87 Matorras, R., Andrés, M., Mendoza, R., Prieto, B., Pijoan, J.I., Expósito, A., Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. Eur J Obstet Gynecol Reprod Biol 170 (2013), 439–443 Level I.
88. 88 Seow, K.M., Lin, Y.H., Bai, C.H., Chen, H.J., Hsieh, B.C., Huang, L.W., et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online 26 (2013), 562–568 Level I.
89. 89 Shaltout, A., Shohyab, A., Youssef, M.A., Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 165 (2012), 254–258 Level I.
90. 90 Leitao, V.M., Moroni, R.M., Seko, L.M., Nastri, C.O., Martins, W.P., Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 101 (2014), 664–675 Level III.
91. 91 Isik, A.Z., Gokmen, O., Zeyneloglu, H.B., Kara, S., Keles, G., Gulekli, B., Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. Eur J Obstet Gynecol Reprod Biol 70 (1996), 179–183 Level I.
92. 92 Shalev, E., Giladi, Y., Matilsky, M., Ben-Ami, M., Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum Reprod 10 (1995), 1373–1376 Level I.
93. 93 Shoham, Z., Weissman, A., Barash, A., Borenstein, R., Schachter, M., Insler, V., Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 62 (1994), 137–142 Level I.
94. 94 Bellver, J., Munoz, E.A., Ballesteros, A., Soares, S.R., Bosch, E., Simón, C., et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18 (2003), 2283–2288 Level I.
95. 95 Ben-Chetrit, A., Eldar-Geva, T., Gal, M., Huerta, M., Mimon, T., Algur, N., et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 16 (2001), 1880–1884 Level I.
96. 96 Isikoglu, M., Berkkanoglu, M., Senturk, Z., Ozgur, K., Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil Steril 88 (2007), 982–985 Level I.
97. 97 Jee, B.C., Suh, C.S., Kim, Y.B., Kim, S.H., Choi, Y.M., Kim, J.G., et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 70 (2010), 47–54 Level III.
98. 98 Venetis, C.A., Kolibianakis, E.M., Toulis, K.A., Goulis, D.G., Papadimas, I., Tarlatzis, B.C., Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril 95 (2011), 188–196 196 e1–3. Level III.
99. 99 Youssef, M.A., Al-Inany, H.G., Evers, J.L., Aboulghar, M., Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev, 2011, CD001302 Level III.
100. 100 El-Khayat, W., Elsadek, M., Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial. Fertil Steril 103 (2015), 101–105 Level I.
101. 101 Gurgan, T., Demirol, A., Guven, S., Benkhalifa, M., Girgin, B., Li, T.C., Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 96 (2011), 53–57 Level II-2.
102. 102 Naredi, N., Karunakaran, S., Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome. J Hum Reprod Sci 6 (2013), 248–252 Level II-1.
103. 103 Shaker, A.G., Zosmer, A., Dean, N., Bekir, J.S., Jacobs, H.S., Tan, S.L., Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 65 (1996), 992–996 Level I.
104. 104 Ferraretti, A.P., Gianaroli, L., Magli, C., Fortini, D., Selman, H.A., Feliciani, E., Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 14 (1999), 1457–1460 Level I.
105. 105 D'Angelo, A., Amso, N., Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev, 2007, CD002806 Level III.
106. 106 Rova, K., Passmark, H., Lindqvist, P.G., Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 97 (2012), 95–100 Level II-2.
107. 107 Borenstein, R., Elhalah, U., Lunenfeld, B., Schwartz, Z.S., Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 51 (1989), 791–795 Level II-2.
108. 108 Casals, G., Fabregues, F., Pavesi, M., Arroyo, V., Balasch, J., Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis study. Acta Obstet Gynecol Scand 92 (2013), 686–691 Level II-3.
109. 109 Lincoln, S.R., Opsahl, M.S., Blauer, K.L., Black, S.H., Schulman, J.D., Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet 19 (2002), 159–163 Level II-2.
110. 110 Qublan, H.S., Al-Taani, M.I., Megdadi, M.F., Metri, R.M., Al-Ahmad, N., Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome. J Obstet Gynaecol 32 (2012), 379–382 Level II-2.
111. 111 Shrivastav, P., Nadkarni, P., Craft, I., Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod 9 (1994), 812–814 Level II-2.
112. 112 Abramov, Y., Fatum, M., Abrahamov, D., Schenker, J.G., Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 75 (2001), 1228–1230 Level II-2.
113. 113 Morris, R.S., Miller, C., Jacobs, L., Miller, K., Conservative management of ovarian hyperstimulation syndrome. J Reprod Med 40 (1995), 711–714 Level II-3.